From mutation identification to therapy: discovery and origins of the first approved gene therapy in the Western world

John J. P. Kastelein; Colin J. D. Ross; Michael R. Hayden

doi:https://doi.org/10.1089/hum.2013.063

From mutation identification to therapy: discovery and origins of the first approved gene therapy in the Western world

John J. P. Kastelein, Colin J. D. Ross, Michael R. Hayden

Research output: Contribution to journal › Editorial › Academic › peer-review

40 Citations (Scopus)

Abstract

On November 2, 2012, Glybera® (alipogene tipovarvec) was the first human gene therapy to receive long awaited market approval in the Western world. This important milestone is expected to open the door to additional gene therapies for the treatment of many diseases in the future. The development of this new gene therapy involved the dedicated contributions from many people from around the world

Original language	English
Pages (from-to)	472-478
Journal	Human gene therapy
Volume	24
Issue number	5
DOIs	https://doi.org/10.1089/hum.2013.063
Publication status	Published - 2013

Access to Document

https://doi.org/10.1089/hum.2013.063

Cite this

@article{f7c2d7160e5b49958a853e56565dc1bb,

title = "From mutation identification to therapy: discovery and origins of the first approved gene therapy in the Western world",

abstract = "On November 2, 2012, Glybera{\textregistered} (alipogene tipovarvec) was the first human gene therapy to receive long awaited market approval in the Western world. This important milestone is expected to open the door to additional gene therapies for the treatment of many diseases in the future. The development of this new gene therapy involved the dedicated contributions from many people from around the world",

author = "Kastelein, {John J. P.} and Ross, {Colin J. D.} and Hayden, {Michael R.}",

year = "2013",

doi = "https://doi.org/10.1089/hum.2013.063",

language = "English",

volume = "24",

pages = "472--478",

journal = "Human gene therapy",

issn = "1043-0342",

publisher = "Mary Ann Liebert Inc.",

number = "5",

}

TY - JOUR

T1 - From mutation identification to therapy: discovery and origins of the first approved gene therapy in the Western world

AU - Kastelein, John J. P.

AU - Ross, Colin J. D.

AU - Hayden, Michael R.

PY - 2013

Y1 - 2013

N2 - On November 2, 2012, Glybera® (alipogene tipovarvec) was the first human gene therapy to receive long awaited market approval in the Western world. This important milestone is expected to open the door to additional gene therapies for the treatment of many diseases in the future. The development of this new gene therapy involved the dedicated contributions from many people from around the world

AB - On November 2, 2012, Glybera® (alipogene tipovarvec) was the first human gene therapy to receive long awaited market approval in the Western world. This important milestone is expected to open the door to additional gene therapies for the treatment of many diseases in the future. The development of this new gene therapy involved the dedicated contributions from many people from around the world

U2 - https://doi.org/10.1089/hum.2013.063

DO - https://doi.org/10.1089/hum.2013.063

M3 - Editorial

C2 - 23578007

SN - 1043-0342

VL - 24

SP - 472

EP - 478

JO - Human gene therapy

JF - Human gene therapy

IS - 5

ER -